|
Cancer typea
|
S ~ Dd
|
S ~ D + Ee
|
PS ~ Df
|
PS ~ D + Eg
|
|---|
|
Beta
|
P
|
Beta
|
P
|
Beta
|
P
|
Beta
|
P
|
|---|
|
bladder
|
0.430
|
1.7 × 10− 3
|
0.082
|
0.68
|
0.354
|
9.4 × 10− 3
|
0.000
|
0.99
|
|
breast
|
−0.281
|
5.6 × 10− 3
|
−0.620
|
2.8 × 10− 6
|
− 0.287
|
4.8 × 10− 3
|
− 0.50
|
1.4 × 10− 4
|
|
cervical
|
0.281
|
0.19
|
0.017
|
0.96
|
0.278
|
0.20
|
−0.063
|
0.84
|
|
lungb
|
−0.048
|
0.78
|
−0.282
|
0.07
|
−0.124
|
0.48
|
−0.449
|
0.03
|
|
lungc
|
0.511
|
0.13
|
0.077
|
0.88
|
0.385
|
0.25
|
−0.190
|
0.70
|
|
head and neck
|
0.160
|
0.42
|
−0.067
|
0.85
|
0.284
|
0.16
|
0.065
|
0.85
|
|
stomach
|
−0.141
|
0.67
|
−0.319
|
0.42
|
−0.060
|
0.86
|
−0.074
|
0.85
|
|
pancreas
|
−0.439
|
0.39
|
−0.571
|
0.29
|
−0.388
|
0.45
|
−0.498
|
0.36
|
|
thyroid
|
0.029
|
0.85
|
−0.238
|
0.19
|
0.025
|
0.87
|
−0.231
|
0.20
|
|
kidney
|
0.323
|
0.17
|
0.14
|
0.59
|
0.292
|
0.21
|
0.105
|
0.69
|
- “a” Sample size for each cancer type: bladder (N = 286), breast (N = 734), cervical (N = 133), lung adenocarcinoma (N = 363), lung squamous carcinoma (N = 85), head and neck (N = 323), stomach (N = 66), pancreas (N = 90), thyroid (N = 333), kidney (N = 143). “b” and “c” refers to lung adenocarcinoma and lung squamous carcinoma, respectively. “d”: APOBEC-mutational signature ~ Germline APOBEC3A/B deletion; “e”: APOBEC-mutational signature ~ Germline APOBEC3A/B deletion + uc003awn + uc003awo + uc011aoc (Expression levels); “f”: Proportion of APOBEC-mutational signature ~ Germline APOBEC3A/B deletion; “g”: Proportion of APOBEC-mutational signature ~ Germline APOBEC3A/B deletion + uc003awn + uc003awo + uc011aoc (Expression levels); In association models: “S” refers to APOBEC-mutational signature; “D” refers to germline APOBEC3A/B deletion; “E” refers to isoform expression levels; “RS” refers to proportion APOBEC-mutational signature. The significance level at P = 0.005, corresponding to a threshold with a Bonferroni-correction of P = 0.05, given 10 tests
